Hypoechoic focal liver lesions: characterization with contrast enhanced ultrasonography

J Clin Ultrasound. 2005 May;33(4):164-72. doi: 10.1002/jcu.20111.

Abstract

Purpose: To evaluate the late sinusoidal phase of contrast enhancement with a 2nd-generation ultrasound contrast enhanced medium in the characterization of hypoechoic focal liver lesions.

Methods: We studied 88 hypoechoic liver lesions (diameter range, 1-18 cm; with 18 lesions 2 cm or less) found on conventional grayscale sonography (US) with contrast-enhanced ultrasonography (CEUS). Final diagnosis was made using contrast enhanced helical CT, contrast enhanced MR, angiography (DSA), and/or histopathic confirmation or clinical imaging follow-up.

Results: There were 37/88 benign lesions demonstrated: 17 cavernous hemangiomas, 3 capillary hemangiomas, 11 focal nodular hyperplasias (FNH), 3 focal areas of sparing in hepatic steatosis, 2 adenomas, and 1 intrahepatic necrotic area. Malignant lesions demonstrated included 51/88: 27 hepatocellular carcinomas (HCC) in cirrhosis, 11 metastatic carcinomas, 10 metastatic endocrine tumors, 2 cholangiocellular carcinomas (CCC) and 1 non-Hodgkin's lymphoma (NHL). CEUS characterized 30/37 (81%) benign lesions and 45/51 (88%) malignant lesions. On the basis of the results obtained during the sinusoidal contrast enhanced phase of CEUS, diagnosis of benignancy was possible in 35/37 (95%) of benign liver lesions and diagnosis of malignancy in 49/51 (96%) of malignant liver lesions. The enhancement pattern of 13 small (< or = 2 cm in diameter) hypervascular liver lesions (3 capillary hemangiomas, 2 FNHs, 4 HCCs, 4 metastatic endocrine tumors) was better demonstrated on CEUS than on helical CT. In these cases the hyper vascularization of the lesions shown on CEUS was not confirmed on CT.

Conclusions: CEUS distinguished malignant from benign hypoechoic liver lesions with an accuracy of 95%.

MeSH terms

  • Angiography, Digital Subtraction
  • Contrast Media / administration & dosage*
  • Female
  • Humans
  • Liver Diseases / diagnosis
  • Liver Diseases / diagnostic imaging*
  • Magnetic Resonance Imaging
  • Male
  • Phospholipids / administration & dosage*
  • Prospective Studies
  • Sulfur Hexafluoride / administration & dosage*
  • Tomography, X-Ray Computed
  • Ultrasonography / methods*

Substances

  • Contrast Media
  • Phospholipids
  • contrast agent BR1
  • Sulfur Hexafluoride